Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa). (TeriCa)
Secondary Hyperparathyroidism, Chronic Kidney Disease-Mineral and Bone Disorder, Dialysis
About this trial
This is an interventional treatment trial for Secondary Hyperparathyroidism focused on measuring Parathyroidectomy, Teriparatide, Parathyroid hormone
Eligibility Criteria
Inclusion Criteria:
- Age > 18 years;
- Patients with end-stage renal disease (ESRD) receiving hemodialysis or peritoneal dialysis treatment > 3 months prior surgery;
- Severe secondary hyperparathyroidism defined as iPTH level > 800 pg/ml, followed with hypercalcemia and/or hyperphosphatemia; with presence of one or more nodular or diffuse parathyroid hyperplasia confirmed with CT;
- Performed total parathyroidectomy with autotransplantation of the parathyroid tissue.
Exclusion Criteria:
- Emergency surgery;
- Primary hyperparathyroidism as a cause of ESRD;
- Scheduled (before surgery) blood transfusion;
- Re-operative surgery;
- Known allergy to the study drug.
- Malignant neoplasms of bone tissue (primary or metastatic).
Sites / Locations
- Saint-Petersburg State University Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Teriparatide group (11 patients)
Control group (9 patients)
Dialysis-dependent patients underwent total parathyroidectomy with autotransplantation of parathyroid tissue, who will receive subcutaneous injections ot recombinant parathyroid hormone (Teriparatide) after surgery in addition to the standard local protocol for hypocalcemia treatment.
Dialysis-dependent patients underwent total parathyroidectomy with autotransplantation of parathyroid tissue, receiving standard local protocol for hypocalcemia treatment (2 micrograms of alphacalcidol plus 4 grams of oral calcium daily).